behphar
Behphar is a Tehran-based pharmaceutical holding company coordinating six wholly-owned subsidiaries across manufacturing, distribution, licensing and import, consumer health, plasma-derived biologics, and specialty therapeutics, serving Iran's healthcare market through pharmacies, hospitals, and patients.
- Company typePrivate
- Founded2010
- HeadquartersTehran, Iran
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What behphar does
Behphar Pharmaceutical Holding is a privately-held pharmaceutical group headquartered in Tehran, Iran, organized as a holding company over six wholly-owned subsidiaries that together cover the full pharmaceutical value chain. The subsidiaries operate in branded and generic manufacturing, importation and licensing of global pharma products, wholesale distribution, consumer health, plasma-derived biologics, and specialty therapeutics. The group serves Iran's healthcare market exclusively, supplying medicines and consumer health products to pharmacies, hospitals, healthcare providers, and end patients.
The group's manufacturing subsidiary operates GMP-certified facilities producing tablets, capsules, sterile vials, and other dosage forms, with annual capacity exceeding 350 million tablets/capsules, 20 million vials, and 400 million other dosage forms. Its distribution arm maintains 100% country coverage through 20+ distribution centers and a fleet of 160+ cold-chain vehicles compliant with GDP standards. The group's plasma collection infrastructure holds capacity for 200,000+ litres, supporting production of plasma-derived biological therapies. Compliance with GMP, GDP, and GSP standards is maintained across the platform, and the group operates a proprietary TRACE traceability system linking manufacturing, distribution, and dispensing nodes.
Behphar's business model integrates manufacturing, importation and licensing, wholesale distribution, and consumer marketing within a single corporate umbrella, capturing margin at multiple stages of the value chain rather than at a single link. Revenue is generated through B2B sales to pharmacies and healthcare institutions, consumer health product sales to end users, and licensing or distribution fees from global pharmaceutical manufacturers seeking an in-country partner in Iran. The group is privately held with no public revenue disclosure, and operations are confined to Iran, exposing the business to country-specific economic, regulatory, and geopolitical risk factors including currency volatility, sanctions, and pharmaceutical price controls.
behphar firmographics
Firmographics- Name
- behphar
- Legal name
- Behphar Pharmaceutical Holding
- Website
- https://behphar.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Behphar is a Tehran-based pharmaceutical holding company coordinating six wholly-owned subsidiaries across manufacturing, distribution, licensing and import, consumer health, plasma-derived biologics, and specialty therapeutics, serving Iran's healthcare market through pharmacies, hospitals, and patients.
- Ownership category
- akta.pro rank
behphar industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Specialty Pharmaceutical Distributors (HLAIAJAB), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)
Keywords
Where behphar is headquartered
LocationHeadquarters
- HQ city
- Tehran
- HQ country
- Iran
- HQ region
- Middle East
Offices1 record
Markets served
behphar business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Manufacturing and Sales: Domestic manufacturing of finished pharmaceutical products (tablets, capsules, injectables, liquid and sterile dosage forms) sold to healthcare providers, pharmacies, and hospitals across Iran
- Licensing and Importation: Market access services introducing high-value international therapies into Iran through licensing partnerships with global manufacturers, commercialization, and regulatory registration
- National Distribution Services: Nationwide pharmaceutical distribution and logistics services through temperature-controlled network covering 100% of Iran
- Consumer Healthcare Products: Sale of wellness, preventive care, OTC products, enzyme-based supplements, herbal medicines, skincare, and functional foods through Behestan Behdasht
- Plasma-Derived Biologics: Collection and processing of plasma for life-saving therapies and biologic treatments
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
behphar product offering
Product offeringCore offering
Behphar Pharmaceutical Holding is an integrated pharmaceutical group operating across the full pharmaceutical value chain in Iran. The group conducts GMP-certified manufacturing of solid, liquid, and sterile dosage forms, licenses and imports finished international therapies, runs a nationwide temperature-controlled distribution and logistics network, collects plasma for biologic therapies, and sells consumer healthcare and specialty therapeutics (ophthalmic, orphan, and rare-disease treatments) through six wholly-owned subsidiaries.
Product overview
Behphar Pharmaceutical Holding operates as an integrated pharmaceutical ecosystem with a platform-plus-specialists architecture. The holding coordinates six specialized subsidiaries: Behestan Darou (market access and international licensing), Darousazi Behestan (GMP-certified domestic manufacturing), Behestan Pakhsh (nationwide distribution and logistics), Behestan Behdasht (consumer health and wellness), Behestan Plasma (plasma collection and biologics), and Valean Darou (specialty therapeutics in ophthalmology and rare diseases). Each subsidiary owns a defined segment of the pharmaceutical value chain, from manufacturing and importation through distribution and specialty care, unified under shared quality governance.
Differentiator
Problem solved
Functional benefit
Products and services
- Behestan Darou — Market Access and International Licensing Importation, licensing, commercialization, and regulatory registration of high-value international pharmaceutical therapies for the Iranian market; serves global manufacturers seeking Iran market entry.
- Darousazi Behestan — GMP-Certified Pharmaceutical Manufacturing Domestic GMP-certified manufacturing of finished pharmaceutical products (tablets, capsules, injectables, and other dosage forms) with technology transfer capability; serves hospitals, pharmacies, and healthcare institutions across Iran.
- Behestan Pakhsh — Nationwide Pharmaceutical Distribution and Logistics Nationwide pharmaceutical distribution with temperature-controlled cold-chain operations, 20+ regional distribution centers, 160+ vehicles, 20,000+ m² logistics space, and end-to-end traceability; serves pharmacies, hospitals, and healthcare institutions across Iran.
- Behestan Behdasht — Consumer Healthcare and Wellness Products Consumer health and wellness products including enzyme-based supplements, herbal medicines, skincare, and functional foods sold over-the-counter to end consumers for everyday health and preventive care.
- Behestan Plasma — Plasma Collection and Biologics Donor-centered plasma collection with hemovigilance protocols and 200,000+ litres annual capacity across major plasma centers in Iran; supports access to plasma-derived medicinal products for life-saving therapies.
- Valean Darou — Specialty Therapeutics Specialty therapeutics company providing ophthalmic, orphan, and rare-disease treatments, expanding access to advanced therapeutic care using biologic therapies.
Quantifiable outcome
- 100% country coverage through national logistics network
- +2 more outcomes
Companies that use behphar
Customer profileSegments3 records
Ideal customer profiles3 records
behphar technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
behphar partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Global Pharmaceutical ManufacturerscoreBehestan Darou collaborates with global pharmaceutical manufacturers to introduce high-value therapies into Iran through licensing, partnership, and full regulatory registration. The company maintains global partnerships with international manufacturers for market access and commercialization of innovative products.
Scale indicators12 records
Recent moves13 records
Expansion highlights5 records
behphar competitors and assessment
Company assessmentBroad incumbents
- McKesson: World's largest pharmaceutical distributor with extensive cold-chain and specialty distribution. Directly comparable to Behestan Pakhsh's nationwide, temperature-controlled distribution platform.
- Cardinal Health: Major U.S. pharmaceutical wholesale distributor with strong nuclear and specialty pharmacy distribution. Comparable to Behestan Pakhsh's nationwide pharma distribution model.
- Teva Pharmaceutical Industries: Global leader in generic finished dosage form manufacturing. Closely comparable to Darousazi Behestan across solid, liquid, and sterile generic manufacturing.
Direct peers
- Sobhan Oncology: Iranian oncology-focused pharmaceutical manufacturer. Comparable to Valean Darou's specialty/rare-disease therapeutics positioning and to the group's biologic therapy investments.
- CSL Behring: Leading manufacturer of plasma-derived and recombinant biologic therapies. Comparable to Behestan Plasma's plasma-derived medicinal products and Valean Darou's specialty biologics.
- Grifols: Global leader in plasma collection and plasma-derived therapies. Closely comparable to Behestan Plasma/Behestan Plasma Alborz's plasma collection and biologic therapy operations.
- Barakat Pharmaceutical Group: Iranian integrated pharmaceutical holding combining manufacturing, distribution, and biotech. Directly comparable as a vertically organized domestic pharma group serving the same market.
- Darou Pakhsh: Iran's largest pharmaceutical distribution and wholesaling group. Directly comparable to Behestan Pakhsh in pharma distribution and to Behphar's integrated manufacturing-distribution model in Iran.
- Tehran Darou Pharmaceutical: Major Iranian pharmaceutical manufacturer producing a broad portfolio of finished dosage forms. Closely comparable to Darousazi Behestan's GMP manufacturing operations and domestic generics focus.
Emerging players
- Cipla: Large emerging-market generic pharmaceutical manufacturer with broad dosage-form portfolio. Comparable to Darousazi Behestan in emerging-market generic manufacturing and access-focused strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
behphar social profiles
Digital presencebehphar financial estimates
Financial estimateRevenue estimate
Valuation estimate
behphar leadership team
Management profileNumber of profiles
behphar subsidiaries and ownership
Company hierarchySubsidiaries7 records
behphar funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
behphar M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about behphar
What does behphar do?
Behphar Pharmaceutical Holding is an integrated pharmaceutical group operating across the full pharmaceutical value chain in Iran. The group conducts GMP-certified manufacturing of solid, liquid, and sterile dosage forms, licenses and imports finished international therapies, runs a nationwide temperature-controlled distribution and logistics network, collects plasma for biologic therapies, and sells consumer healthcare and specialty therapeutics (ophthalmic, orphan, and rare-disease treatments) through six wholly-owned subsidiaries.
Is behphar a public or private company?
behphar is a private company. It is classified as unknown and is currently operating.
When was behphar founded?
behphar was founded in 2010. It employs 11 to 50 people.
Where is behphar based?
behphar is headquartered in Tehran, Iran, in the Middle East region.
How does behphar make money?
Five revenue lines are on record. Pharmaceutical Manufacturing and Sales are the primary driver. The others are licensing and Importation, national Distribution Services, consumer Healthcare Products and plasma-Derived Biologics.
Who are behphar's main competitors?
Broad incumbents on record are McKesson, Cardinal Health and Teva Pharmaceutical Industries. Direct peers are Sobhan Oncology, CSL Behring, Grifols, Barakat Pharmaceutical Group, Darou Pakhsh and Tehran Darou Pharmaceutical. Cipla is listed as an emerging player.
Does behphar have an API?
No public API is recorded for behphar.
What industry is behphar in?
behphar's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.